Newsroom

TURIN, Italy--(BUSINESS WIRE)--Today, the Board of Directors of Reply S.p.A. [EXM, STAR: REY] approved the results as at 31 March 2026. Since the beginning of the year, the Group has recorded a consolidated revenues amounting to €645.0 million, an increase of 6.2% compared to the corresponding data for 2025. All indicators are positive for the period. In the first quarter of 2026 the consolidated EBITDA stood at €112.0 million compared to €105.3 million in 2025, equal to 17.4% of the turnover....

TURIN, Italien--(BUSINESS WIRE)--Der Verwaltungsrat der Reply S.p.A. [EXM, STAR: REY] hat heute die Ergebnisse zum 31. März 2026 genehmigt. Seit Beginn des Jahres verzeichnete die Gruppe einen Konzernumsatz von 645,0 Millionen Euro – dies entspricht einer Steigerung von 6,2% gegenüber dem Vergleichszeitraum 2025. Alle Kennzahlen des Berichtszeitraums waren positiv. Im ersten Quartal 2026 betrug das konsolidierte EBITDA 112,0 Millionen Euro im Vergleich zu 105,3 Mio. im Jahr 2025 und entspricht...

TORINO, Italia--(BUSINESS WIRE)--Il Consiglio di Amministrazione di Reply S.p.A. [EXM, STAR: REY] ha approvato oggi i risultati al 31 marzo 2026. Da inizio anno, il Gruppo ha registrato ricavi consolidati pari a 645,0 milioni di euro, in incremento del 6,2% rispetto al corrispondente periodo del 2025. Positivi tutti gli indicatori del periodo. Nel primo trimestre 2026 l’EBITDA consolidato è stato pari a 112,0 milioni di euro rispetto ai 105,3 milioni di euro registrati nel 2025 ed è pari al 17,...

TOKYO--(BUSINESS WIRE)--  Meiji Seika Pharma: risultati positivi da Integral-1, lo studio clinico di fase III su nacubactam, un nuovo inibitore delle β-lattamasi, nel trattamento delle infezioni del tratto urinario complicate o nella pielonefrite acuta non complicata, pubblicati in The Lancet Meiji Seika Pharma Co., Ltd. (con sede a Tokyo; Presidente e Direttore rappresentante: Toshiaki Nagasato) oggi ha annunciato che i risultati dello studio Integral-1, uno di due studi clinici globali di fas...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust FactorFX UCITS ETF 14.05.2026 FTFX IE00BD5HBQ97   63,402.00 USD   1,691,529.99   26.679  ...

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon to present 8 abstracts on affordability, access and adoption across women’s health, biosimilar and general medicines portfolio at ISPOR 2026....

NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) ("APi" or the "Company") today announced the closing of two previously announced financing transactions: a private offering of $500 million in aggregate principal amount of 5.75% senior notes due 2034, and an amendment to the Company's existing credit agreement (the "Amendment"), which extends the maturity of the Company's Term Loan B facility to 2033 and upsizes and extends the Company's revolving credit facility to $1.0 b...

VICTORIA, British Columbia--(BUSINESS WIRE)--Vecima will highlight its leadership in next-generation Fiber Access at Fiber Connect 2026 showcasing products from its Entra All-PON portfolio....

BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. “The first quarter of 2026 was transformational for the Company, with the acquisition of Faeth Therapeutics and the concurrent $200 million private placement in February, supported by a group of leading life sciences investors,” said Christopher Gerry, President & General Counsel of Sensei Biotherapeutics. “This ac...

DAYTON, Ohio--(BUSINESS WIRE)--REX American Resources Corporation (“REX” or the “Company”) (NYSE: REX), a leading ethanol production company, announced today that it will report its fiscal first quarter 2026 operational and financial results on Thursday, May 28th, 2026 pre-market and will host a conference call and webcast at 11:00 a.m. ET that morning to review the results. To access the conference call, interested parties may dial (877) 269-7751 (US) or (201) 389-0908 (international). Partici...